Krystal Biotech's (KRYS) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note released on Wednesday morning,Benzinga reports. They currently have a $219.00 target price on the stock. Chardan Capital also issued estimates for Krystal Biotech's FY2026 earnings at $8.80 EPS.

A number of other research analysts have also recently issued reports on KRYS. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. HC Wainwright reissued a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $218.63.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $4.94 during trading on Wednesday, hitting $132.23. 329,798 shares of the company's stock traded hands, compared to its average volume of 299,978. The company has a market cap of $3.82 billion, a PE ratio of 44.22 and a beta of 0.79. The firm's fifty day moving average price is $171.56 and its 200 day moving average price is $170.06. Krystal Biotech has a twelve month low of $131.71 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. As a group, equities research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRYS. Fifth Third Bancorp raised its holdings in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech in the third quarter valued at about $40,000. GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech in the fourth quarter valued at about $95,000. Covestor Ltd increased its position in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares during the period. Finally, Avanza Fonder AB acquired a new stake in Krystal Biotech in the 4th quarter worth about $119,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).